{"id":"brii-179","_chembl":{"chemblId":"CHEMBL3667004","moleculeType":"Small molecule","molecularWeight":"556.68"},"_dailymed":null,"_scrapedAt":"2026-03-28T03:58:08.900Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123203,"model":"claude-sonnet-4-5-20250929"},"description":"BRII-179 is an investigational therapeutic developed by Brii Biosciences Limited, currently in Phase 2 clinical development. Limited public information is available regarding its molecular target, mechanism of action, or specific therapeutic indications at this time.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"trialDetails":[{"nctId":"NCT05970289","phase":"PHASE2","title":"Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brii Biosciences Limited","startDate":"2023-08-22","conditions":"Chronic Hepatitis B Virus Infection","enrollment":86},{"nctId":"NCT06650852","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)","status":"RECRUITING","sponsor":"Brii Biosciences Limited","startDate":"2024-10-31","conditions":"Chronic Hepatitis B Virus (HBV) Infection","enrollment":250},{"nctId":"NCT06491563","phase":"PHASE2","title":"Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brii Biosciences Limited","startDate":"2024-08-06","conditions":"For Treatment of Chronic Hepatitis B Virus Infection","enrollment":150},{"nctId":"NCT04749368","phase":"PHASE2","title":"Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection","status":"COMPLETED","sponsor":"Brii Biosciences Limited","startDate":"2021-04-12","conditions":"Hepatitis B, Chronic","enrollment":91}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BRII-179","genericName":"BRII-179","companyName":"Brii Biosciences Limited","companyId":"brii-biosciences-limited","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}